Efficacy and safety of valganciclovir in liver‐transplanted children infected with Epstein‐Barr virus
Loreto Hierro, Ruth Díez‐Dorado, Carmen Díaz, Angela De la Vega, Esteban Frauca, Carmen Camarena, Gema Muñoz‐Bartolo, Ana González de Zárate, Manuel López Santamaría, Paloma Jara – 30 July 2008 – Epstein‐Barr virus (EBV) infection after liver transplantation (LT) is associated with increased risk of posttransplant lymphoproliferative disorder (PTLD). Lowering immunosuppression is the current method to prevent PTLD in LT children with a high viral load. The aim of this study was to assess the efficacy and safety of valganciclovir (VGCV) in children with EBV infection after LT.